The U.S. Food and Drug Administration has granted Fast Track Designation to the Company’s development program to investigate INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer who have failed at least 2 prior lines of therapy. Intensity has designed a Phase 3 program for INT230-6 for Metastatic Breast Cancer and would have potential to initiate other Phase 3 programs.
New Product Development
New product formulations with more potency to treat cancer are being researched. The Company’s DfuseRxSM platform technology can rapidly identify novel tissue dispersion and cell penetrating anti-cancer formulations based on tumor type.